The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Departments of Medical Oncology and Urology, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD.
Department of Urology & Greenberg Bladder Cancer Institute, Johns Hopkins University, Baltimore, MD.
Urol Oncol. 2021 Oct;39(10):619-622. doi: 10.1016/j.urolonc.2021.05.013. Epub 2021 Jun 18.
Enfortumab vedotin (EV) was FDA approved in December 2019 for platinum- and checkpoint-refractory urothelial cancer based on an exceptional 44% response rate, and is currently approved for use after platinum and checkpoint inhibitor therapy. Enfortumab is an antibody-drug conjugate that targets Nectin-4, which is widely expressed in urothelial cancer. Despite this ample target, clinical benefit is not achieved by all patients, and mechanisms of treatment resistance are undescribed. Herein we summarize what is known to date regarding coorelative findings and subgroup analysis and EV response, including novel biopsy data in patients with tumor progression post EV.
恩福妥单抗（EV）于 2019 年 12 月基于 44%的卓越缓解率获得 FDA 批准，用于铂类和检查点抑制剂难治性尿路上皮癌，目前批准用于铂类和检查点抑制剂治疗后使用。恩福妥单抗是一种抗体药物偶联物，靶向广泛表达于尿路上皮癌的 Nectin-4。尽管有广泛的靶标，但并非所有患者都能获得临床获益，且治疗耐药的机制尚未明确。本文总结了迄今为止关于相关性发现和亚组分析与 EV 反应的研究，包括 EV 治疗后肿瘤进展患者的新型活检数据。
